
Veru VERU
€ 2.63
1.61%
Quartalsbericht 2026-Q2
hinzugefügt 13.05.2026
Veru EV 2011-2026 | VERU
EV Jährlich Veru
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 80.7 M | 14 M | 121 M | 535 M | 407 M | 190 M | 147 M | 82 M | 45.8 M | 29.5 M | 49 M | 128 M | 266 M | 189 M | 117 M | 1.49 B | 1.08 B | -1.92 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.49 B | -1.92 M | 276 M |
EV anderer Aktien in der Arzneimittelhersteller
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Endo International plc
ENDP
|
-710 M | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
-3.12 M | - | - | $ 36.6 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
126 M | $ 5.66 | 0.98 % | $ 84.1 M | ||
|
HEXO Corp.
HEXO
|
560 M | - | 2.45 % | $ 38.1 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-974 M | - | -0.1 % | $ 2.03 B | ||
|
AcelRx Pharmaceuticals
ACRX
|
6.79 M | - | 7.5 % | $ 6.35 M | ||
|
DURECT Corporation
DRRX
|
-11 M | - | - | $ 50.1 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
28.5 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
737 M | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
25.3 M | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
197 M | - | - | $ 142 M | ||
|
Cronos Group
CRON
|
-1.35 M | $ 2.72 | 1.49 % | $ 1.04 B | ||
|
Athenex
ATNX
|
209 M | - | -23.39 % | $ 1.76 M | ||
|
Harrow Health
HROW
|
2.21 B | $ 38.34 | 1.86 % | $ 1.41 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
756 M | - | - | $ 2.06 B | ||
|
Catalent
CTLT
|
16.7 B | - | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
457 M | - | -39.89 % | $ 27.7 M | ||
|
Canopy Growth Corporation
CGC
|
459 M | $ 1.03 | 3.01 % | $ 111 M | ||
|
Organogenesis Holdings
ORGO
|
408 M | $ 2.42 | 3.21 % | $ 307 M | ||
|
Pacira BioSciences
PCRX
|
1.68 B | $ 23.0 | 0.04 % | $ 1.06 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
7.57 M | $ 1.12 | 2.75 % | $ 1.39 M | ||
|
Aurora Cannabis
ACB
|
330 M | $ 3.17 | 4.11 % | $ 174 M | ||
|
Solid Biosciences
SLDB
|
616 M | $ 7.3 | 2.17 % | $ 639 M | ||
|
Jupiter Wellness
JUPW
|
3.7 M | - | - | $ 33.6 M | ||
|
Lannett Company
LCI
|
671 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
146 M | $ 1.07 | 0.47 % | $ 102 M | ||
|
Tilray
TLRY
|
1.96 B | $ 5.14 | 3.21 % | $ 3.18 B | ||
|
cbdMD
YCBD
|
4.51 M | $ 0.71 | 3.49 % | $ 2.86 M | ||
|
Evolus
EOLS
|
467 M | $ 6.68 | -0.74 % | $ 431 M | ||
|
Sundial Growers
SNDL
|
-17.5 M | $ 1.46 | 2.46 % | $ 3.37 M | ||
|
Emergent BioSolutions
EBS
|
1.04 B | $ 8.41 | 1.08 % | $ 450 M | ||
|
Neoleukin Therapeutics
NLTX
|
-80.1 M | - | - | $ 193 M | ||
|
Assertio Holdings
ASRT
|
238 M | $ 23.49 | 0.02 % | $ 150 M | ||
|
ProPhase Labs
PRPH
|
56.3 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
715 M | - | - | $ 1.42 B | ||
|
Bausch Health Companies
BHC
|
26.7 B | $ 5.13 | 1.38 % | $ 1.9 B | ||
|
PetIQ
PETQ
|
280 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
251 M | $ 6.64 | -0.15 % | $ 262 M | ||
|
Recro Pharma
REPH
|
220 M | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
84.7 M | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
26.3 M | $ 4.25 | 0.47 % | $ 212 M | ||
|
PLx Pharma
PLXP
|
75 M | - | -27.8 % | $ 2.56 M | ||
|
Viatris
VTRS
|
21.2 B | $ 16.43 | -0.27 % | $ 19.2 B | ||
|
Zomedica Corp.
ZOM
|
2.62 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-22.6 M | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
43.3 M | $ 0.64 | 2.32 % | $ 23 M | ||
|
Tricida
TCDA
|
555 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
10.7 M | $ 0.77 | 7.74 % | $ 3.3 M | ||
|
TherapeuticsMD
TXMD
|
26.3 M | $ 2.29 | 4.09 % | $ 26.5 M |